NASHVILLE, TN – In a comprehensive update to stakeholders, researchers, and the patient community, METAvivor Research and Support Inc. has officially opened its 2026 grant cycle. The announcement, delivered by the organization’s President, Dr. Kelly Shanahan, comes at a pivotal moment for the metastatic breast cancer (MBC) community, characterized by a surge in research interest, a precarious federal funding environment, and a paradigm shift toward patient-centered clinical trial design.
As the only national non-profit organization that dedicates 100% of its net proceeds to metastatic breast cancer research, METAvivor’s 2026 initiative aims to build upon a record-breaking previous year. With the organization witnessing a 100% increase in Letters of Intent (LoIs) during the last cycle, the upcoming year is poised to be a landmark for Stage IV breast cancer advocacy and scientific advancement.
Main Facts: A Strategic Pivot Toward Aggressive Research
The 2026 grant cycle represents a critical pillar in METAvivor’s mission to transition metastatic breast cancer from a terminal diagnosis to a manageable chronic condition. The organization is currently inviting researchers focused exclusively on MBC to submit their applications, emphasizing a need for innovative therapies that address the unique challenges of Stage IV disease.
The Surge in Scientific Interest
According to Dr. Shanahan, the previous grant cycle saw double the usual volume of LoIs. This influx suggests a growing interest within the scientific community to tackle the complexities of metastasis—a field that has historically been underfunded compared to early-stage prevention and awareness. The 2026 cycle is expected to meet or exceed this level of engagement, necessitating a robust review process that involves both scientific experts and "patient-researchers."
Focused Clinical Initiatives: The MSK Trial
A highlight of the current advocacy efforts is a specialized clinical trial led by Dr. Lior Braunstein at Memorial Sloan Kettering (MSK) Cancer Center. This trial explores the efficacy of adding surgical intervention for the primary breast tumor and radiation to metastatic sites in patients with HER2+ oligometastatic breast cancer. Oligometastatic disease refers to a state where cancer has spread to a limited number of sites, suggesting that aggressive local treatment might improve overall survival and progression-free survival—a departure from traditional palliative-only approaches for Stage IV patients.
Operational Expansion and Volunteerism
Beyond research funding, METAvivor is aggressively expanding its infrastructure. The organization has issued a call for volunteers to lead peer-to-peer support groups and join various organizational committees. This expansion is designed to bolster the "Support" half of METAvivor’s mission, ensuring that patients navigating the rigors of clinical trials have access to trained peer advocates.
Chronology: The Road to the 2026 Grant Cycle
The timeline for METAvivor’s 2026 initiatives is structured to maximize scientific rigor while ensuring the rapid deployment of funds to high-impact projects.
- Early 2025: Opening of the LoI Portal: The 2026 grant cycle begins with the submission of Letters of Intent. These brief proposals allow METAvivor’s review board to vet the relevance and feasibility of research projects before inviting full applications.
- Mid-2025: The Review Phase: Following the submission of LoIs, a dual-review process begins. This unique model pairs PhD-level scientists with trained patient advocates to ensure that the research is not only scientifically sound but also holds tangible value for the MBC community.
- Late 2025: Full Application and Selection: Selected researchers are invited to submit comprehensive grant applications. These are rigorously scored, with funding decisions finalized toward the end of the year.
- January 2026: Grant Awarding: Funds are officially disbursed to the selected institutions, coinciding with the start of the 2026 fiscal year for many academic research centers.
- Ongoing 2026: Community Fundraising: Throughout the year, METAvivor will coordinate with independent fundraisers to replenish the research fund, ensuring the sustainability of the 2027 cycle.
Supporting Data: The Funding Gap and "Financial Toxicity"
The necessity of METAvivor’s work is underscored by stark disparities in cancer research funding. While breast cancer is widely recognized and funded, the vast majority of resources are historically directed toward early-stage detection and "cure" narratives, often leaving those already living with metastatic disease behind.
The Metastatic Funding Disparity
Statistical data from the Metastatic Breast Cancer Alliance indicates that while nearly 30% of early-stage breast cancer patients will eventually progress to metastatic disease, only approximately 2% to 5% of all breast cancer research funding is dedicated specifically to the metastatic stage. METAvivor’s 100% commitment model serves as a direct countermeasure to this funding gap.
The Federal Budget Context
Dr. Shanahan highlighted the importance of the federal budget, specifically the proposed increase in funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI). Federal funding remains the largest source of basic science research; however, political volatility often leaves researchers in a state of uncertainty. METAvivor’s private grants provide a critical safety net, allowing researchers to pursue high-risk, high-reward theories that federal grants might overlook.
The Reality of "Financial Toxicity"
Dr. Shanahan’s personal account of participating in a clinical trial at the Sarah Cannon Research Institute in Nashville highlights a growing concern in oncology: financial and "time" toxicity.
- Travel Costs: For patients like Dr. Shanahan, who must fly from California to Tennessee to access cutting-edge trials, the costs of airfare, lodging, and ground transportation can be prohibitive.
- Time Loss: The time spent away from family and support systems adds a psychological burden to the physical toll of treatment.
- Logistical Barriers: The hope to transfer to a trial site closer to home reflects a broader systemic need for "decentralized" clinical trials, which would allow patients to receive care at local clinics rather than traveling to major urban cancer centers.
Official Responses: Leadership and Expert Perspectives
The current outlook for METAvivor is shaped by the dual perspective of its leadership. Dr. Kelly Shanahan serves not only as the President of the organization but also as a physician and a patient living with MBC. This "patient-scientist" perspective is central to the organization’s ethos.
From the President’s Office
In her recent communication, Dr. Shanahan expressed a mix of cautious optimism and urgency. "I love talking to researchers and being a part of research," she noted, emphasizing that the 2026 cycle is not just about the money—it’s about the synergy between those who study the disease and those who live with it. Her recommendation of cultural landmarks in Nashville, such as the Museum of African American Music, serves as a reminder of the "human" side of the patient experience—maintaining a life of quality while undergoing intensive treatment.
The Scientific Perspective: Dr. Lior Braunstein
Representing the clinical frontier, Dr. Lior Braunstein’s work at MSK represents a significant shift in how "oligometastatic" disease is handled. By investigating whether surgery and radiation can improve outcomes in HER2+ patients, Braunstein is challenging the traditional dogma that stage IV cancer should only be treated systemically. If successful, this trial could redefine the standard of care for thousands of patients, offering a more aggressive path toward long-term stability.
Implications: The Future of MBC Advocacy and Treatment
The launch of the 2026 grant cycle and the expansion of METAvivor’s support programs have several long-term implications for the oncology landscape.
Redefining the Standard of Care
The focus on oligometastatic trials (like the MSK study) suggests that the medical community is beginning to view metastatic disease through a more nuanced lens. Instead of a "one-size-fits-all" palliative approach, the future may involve personalized combinations of systemic therapy, targeted radiation, and surgery, tailored to the specific volume of a patient’s metastatic burden.
The Rise of the Patient-Reviewer
By involving patients in the grant review process, METAvivor is ensuring that research remains focused on "outcomes that matter." While a scientist might focus on cellular pathways, a patient reviewer asks, "Will this drug allow me to live long enough to see my child graduate?" or "What are the long-term side effects on quality of life?" This integration is likely to influence how other major funding bodies, including the NCI, approach grant evaluations.
Mobilizing a National Support Network
The call for peer-to-peer support group leaders indicates a move toward a more grassroots, decentralized support model. As treatments allow MBC patients to live longer, the need for community and mental health support becomes a multi-year requirement rather than a short-term crisis intervention.
Conclusion
As METAvivor moves into the 2026 cycle, the organization stands as a bridge between the clinical laboratory and the patient’s bedside. Through the leadership of figures like Dr. Kelly Shanahan and the scientific contributions of researchers like Dr. Lior Braunstein, the MBC community is no longer just a passive recipient of care but an active participant in the search for a cure. With the grant cycle now open, the eyes of the oncology world turn toward the researchers who will receive the funding necessary to turn the tide against metastatic breast cancer.
About METAvivor:
METAvivor Research and Support Inc. is a 501(c)(3) non-profit organization dedicated to the specific fight against metastatic breast cancer. It is the only organization in the US that exclusively funds MBC research through a competitive grant process and directs 100% of its donations to that cause. For more information on applying for the 2026 grant or volunteering, visit metavivor.org.
About the Author
